Details:
The CRL indicates that the FDA has completed its review of the NATPARA, is a prescription parathyroid hormone PAS and determined that it cannot be approved in its present form.
Lead Product(s): Parathyroid Hormone
Therapeutic Area: Endocrinology Product Name: Natpara
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.
Lead Product(s): Upacicalcet Sodium Hydrate
Therapeutic Area: Endocrinology Product Name: Upasita
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Kissei Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021
Details:
The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Lead Product(s): Alogliptin Benzoate,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Liovel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 01, 2021
Details:
The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 26, 2021
Details:
The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: $278.0 million Upfront Cash: $266.0 million
Deal Type: Divestment June 11, 2020